The "tricky business" of identifying mechanisms of resistance to anti-PD-1

James S. Wilmott, Helen Rizos, Richard A. Scolyer, Georgina V. Long*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.

Original languageEnglish
Pages (from-to)2921-2923
Number of pages3
JournalClinical Cancer Research
Issue number12
Publication statusPublished - 15 Jun 2017


Dive into the research topics of 'The "tricky business" of identifying mechanisms of resistance to anti-PD-1'. Together they form a unique fingerprint.

Cite this